Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ET Receptor Antagonist 1 (compound 16h), with an IC50 value of 0.18 nM, is an orally active agent that can be utilized for pulmonary arterial hypertension (PAH) research. It has demonstrated efficacy in mitigating monocrotaline-induced PAH in a rat model [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | ET Receptor Antagonist 1 (compound 16h), with an IC50 value of 0.18 nM, is an orally active agent that can be utilized for pulmonary arterial hypertension (PAH) research. It has demonstrated efficacy in mitigating monocrotaline-induced PAH in a rat model [1]. |
In vivo | ET receptor antagonist 1 (compound 16h), administered orally at dosages of 150 mg/kg/d and 300 mg/kg/d beginning 48 hours post-MCT treatment for a period of 21-26 days, significantly reduced mean pulmonary arterial pressure (mPAP) levels in rats exposed to MCT, and decreased levels of HIF1α, ANP, and TNNI3, exhibiting antioxidant properties and inhibiting lipid peroxidation [1]. |
Molecular Weight | 459.52 |
Formula | C21H25N5O5S |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ET receptor antagonist 1 Endocrinology/Hormones Estrogen Receptor/ERR inhibitor inhibit